CDEK
← All drugs Report issue

inz-701

Recombinant proteinexperimental

Clinical trial activity

7 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Jun 18, 2021 (NCT04686175)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06739980Phase 2Jan 31, 2025Inozyme Pharma
NCT06462547Phase 2Jun 19, 2024Inozyme Pharma
NCT06283589Phase 1Feb 12, 2024Inozyme Pharma
NCT06046820Phase 3Jan 12, 2024Inozyme Pharma
NCT05734196Phase 1May 25, 2023Inozyme Pharma
NCT05030831Phase 1/Phase 2 (Phase 2)Sep 22, 2021Inozyme Pharma, IQVIA
NCT04686175Phase 1/Phase 2 (Phase 2)Jun 18, 2021Inozyme Pharma, IQVIA
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Inozyme PharmaFor profit7732021
IQVIAFor profit2012021
2 organizations
Page 1 / 1